Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Suzhou Zelgen Biopharmaceuticals Co.,Ltd315 enrolled

Overview

This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

315

Conditions

Alopecia Areata

Interventions

JaktinibDRUG

75mg BID

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects voluntarily sign the informed consent form. * Patients who participated in ZGJAK018. Exclusion Criteria: * Subjects who are unsuitable to the trial, as identified by the investigator.

Locations (1)

11 Xizhimen South Street

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Number of subjects reporting treatment-emergent adverse events

Patients with treatment-emergent adverse events/all patients \*100%

Time frame: Baseline through week 24

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.